European Society for Medical Oncology Congress (ESMO)

Data from the CLEOPATRA trial show that pertuzumab adds nearly 16 months to median survival times when used with trastuzumab and chemo in HER2-positive breast cancer, according to final results presented at the ESMO 2014 Congress.

Two French studies have shown that screening for colorectal cancer with fecal occult blood tests can be very effective, according to results presented at the ESMO 2014 Congress.

Exposure to chemo or radiotherapy has no long-term negative mental or cardiac effects on children exposed to these cancer treatments while in the womb, according to a study presented at the 2014 ESMO Congress.

Adding the TKI cediranib to chemotherapy improved progression-free survival in patients with metastatic or relapsed cervical cancer, according to a study presented at the 2014 ESMO Congress.

Continuing gefitinib after acquiring resistance to the TKI adds no clinical benefit in patients with EGFR-positive non-small-cell lung cancer, according to trial results presented at the 2014 ESMO Congress.

Almost three out of every four young oncologists in Europe may be experiencing burnout, according to data from the largest burnout survey conducted to date.

As part of our coverage of the 2014 ESMO meeting we discuss recent advances in the treatment of kidney, bladder, and testicular cancers.